Quantcast

ViiV Healthcare studies on treating HIV with two drug regimen

ViiV Healthcare, majority-owned by GSK, with Pfizer and Shionogi Limited as shareholders, has announced detailed study results from its phase III programme evaluating the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen to a two-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen Sciences Ireland UC).

Read more